March 2, 2022 06:41 AM EST

FDA quickly follows a voluntary pause for CAR-T 2.0 with a clinical hold to investigate 2 patient deaths

Celyad’s voluntary pause didn’t last long.

The biotech put out word after the market closed Monday that the FDA has swiftly followed up

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA quick­ly fol­lows a vol­un­tary pause for CAR-T 2.0 with a clin­i­cal hold to in­ves­ti­gate 2 pa­tient deaths